- Application is being reviewed under the US FDA's Real-Time Oncology Review pilot programme
- Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive early-stage lung cancer, compared with best supportive care
- Tecentriq is the first and only cancer immunotherapy to demonstrate positive Phase III results in the adjuvant lung cancer setting
Basel, 3 August 2021 - Roche
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices
Dr. Nicolas Dunant Phone: +41 61 687 05 17 | Patrick Barth Phone: +41 61 688 44 86 |
Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 | Karsten Kleine Phone: +41 61 682 28 31 |
Nina Mählitz Phone: +41 79 327 54 74 | Nathalie Meetz Phone: +41 61 687 43 05 |
Roche Investor Relations | |
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com (mailto:karl.mahler@roche.com) | Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com (mailto:jon_kaspar.bayard@roche.com) |
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com (mailto:sabine.borngraeber@roche.com) | Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com (mailto:bruno.eschli@roche.com) |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com (mailto:birgit.masjost@roche.com) | Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com (mailto:gerard.tobin@roche.com) |
Investor Relations North America | |
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com (mailto:kalm.loren@gene.com) |
Attachment
- 03082021_MR_ Global Impower010 FDA Acceptance_EN (https://ml-eu.globenewswire.com/Resource/Download/15b1099c-bba8-4573-98fe-76689df66df7)